TLR4 and neoplasm: Preclinical studies have shown that after chronic UVB exposure, compared to the control group, mice treated with the TLR4 inhibitor TAK-242 exhibited a significant reduction in CD4+CD25+ regulatory T cells in the spleen and lymph nodes, decreased expression of Foxp3 and IL-10 in tumor tissue, markedly inhibited skin carcinogenesis, and significant downregulation of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α (168).